Skip to main content
. 2022 Aug 31;14(17):4250. doi: 10.3390/cancers14174250

Table 1.

Baseline patient characteristics by HER2 IHC/FISH status.

Characteristics Total
n = 2296 (%)
HER2 0
n = 368 (%)
HER2 1+
n = 911 (%)
HER2 2+/FISH−
n = 1017 (%)
p-Value
Age (y/o) 0.798
<60 1270 (55.3) 204 (55.4) 511 (56.1) 555 (54.6)
≥60 1026 (44.7) 164 (44.6) 400 (43.9) 462 (45.4)
Gender 0.806
Female 2277 (99.2) 366 (99.5) 903 (99.1) 1008 (99.1)
Male 19 (0.8) 2 (0.5) 8 (0.9) 9 (0.9)
Histology 0.004
IDC 1935 (84.3) 295 (80.2) 756 (83.0) 884 (86.9)
Non-IDC 361 (15.7) 73 (19.8) 155 (17.0) 133 (13.1)
TNM stage 0.020
I 1423 (62.0) 242 (65.8) 588 (64.5) 593 (58.3)
II 859 (37.4) 123 (33.4) 317 (34.8) 419 (41.2)
III 14 (9.6) 3 (0.8) 6 (0.7) 5 (0.5)
Tumor Size 0.050
<2 cm 1227 (53.4) 201 (54.6) 511 (56.1) 515 (50.6)
≥2 cm 1069 (46.6) 167 (45.4) 400 (43.9) 502 (49.4)
Breast surgery 0.372
BCS 1006 (43.8) 166 (45.1) 411 (45.1) 429 (42.2)
Mastectomy 1290 (56.2) 202 (54.9) 500 (54.9) 588 (57.8)
ALN status 0.001
Negative 1919 (83.6) 323 (87.8) 777 (85.3) 819 (80.5)
Positive 377 (16.4) 45 (12.2) 134 (14.7) 198 (19.5)
Histological grade 0.334
I-II 1879 (82.8) 292 (79.3) 755 (82.9) 832 (81.8)
III 417 (18.2) 76 (20.7) 156 (17.1) 185 (18.2)
ER 0.115
Negative 5 (0.2) 1 (0.3) 4 (0.4) 0 (0.0)
Positive 2291 (99.8) 367 (99.7) 907 (99.6) 1017 (100.0)
PR 0.037
Negative 250 (10.9) 54 (14.7) 95 (10.4) 101 (9.9)
Positive 2046 (89.1) 314 (85.3) 816 (89.6) 916 (90.1)
Ki-67 <0.001
<14% 1065 (46.4) 178 (48.4) 467 (51.3) 420 (41.3)
≥14% 1231 (53.6) 190 (51.6) 444 (48.7) 597 (58.7)
Molecular subtype 0.010
Luminal A 733 (31.9) 119 (32.3) 321 (35.2) 293 (28.8)
Luminal B (HER2-) 1563 (68.1) 249 (67.7) 590 (64.8) 724 (71.2)

Abbreviations: HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization; y/o, years old; IDC, invasive ductal carcinoma; BCS, breast-conserving surgery; ALN, axillary lymph node; ER, estrogen receptor; PR, progesterone receptor.